Skip to main content
Erschienen in: Digestive Diseases and Sciences 1/2022

04.02.2021 | Original Article

A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC

verfasst von: Joon Yeul Nam, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Hyo-Cheol Kim, Jin Wook Chung, Jung-Hwan Yoon, Yoon Jun Kim

Erschienen in: Digestive Diseases and Sciences | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Prognosis prediction in patient with hepatocellular carcinoma (HCC) after transarterial radioembolization (TARE) remains difficult. The aim of this study was to develop a prognostic model to aid in the decision to use TARE.

Methods

A total of 174 patients in Korea who underwent TARE for HCC as the initial treatment were included. We developed a prediction model for overall survival (OS) based on independent risk factors for OS and validated the model by bootstrap method.

Results

The median maximal size of the tumors was 8.2 cm, the median number of tumors was 2, and the median albumin level was 4.0 g/dL. Portal vein tumor thrombosis was found in 46.0% (Vp1–3 [39.7%] and Vp4 [6.3%]). Four independent risk factors associated with OS (maximal tumor size, tumor number, albumin, and portal vein tumor thrombosis) were used to develop the SNAP-HCC score. Bootstrap validation of the scoring index determined that the Harrell’s c-index for OS was 0.756 (95% confidence interval: 0.729–0.783). Patients grouped based on their SNAP-HCC (scores 0–5) were well discriminated, with significant differences between the groups (all P < 0.05). Patients with SNAP-HCC < 3 showed significantly longer OS than patients with SNAP-HCC ≥ 3 (P < 0.001). The respective survival probabilities at years 1 and 3 were 0.81 and 0.73 in the low-risk (SNAP-HCC < 3) and 0.32 and 0.14 in the high-risk (SNAP-HCC ≥ 3) patients.

Conclusions

The SNAP-HCC scoring system predicted the outcome of HCC patients undergoing TARE as an initial treatment. This model could be helpful for initial planning the treatment of HCC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Prev Biomarkers 2016;25:16–27CrossRef Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Prev Biomarkers 2016;25:16–27CrossRef
2.
Zurück zum Zitat Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215–220CrossRef Carr BI, Guerra V. A hepatocellular carcinoma aggressiveness index and its relationship to liver enzyme levels. Oncology 2016;90:215–220CrossRef
3.
Zurück zum Zitat Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. LWW: City; 2005.CrossRef Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. LWW: City; 2005.CrossRef
4.
Zurück zum Zitat Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741–1749CrossRef Hilgard P, Hamami M, Fouly AE et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010;52:1741–1749CrossRef
5.
Zurück zum Zitat Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868–878CrossRef Sangro B, Carpanese L, Cianni R et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011;54:868–878CrossRef
6.
Zurück zum Zitat Cillo U, Vitale A, Grigoletto F et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–731CrossRef Cillo U, Vitale A, Grigoletto F et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723–731CrossRef
7.
Zurück zum Zitat Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017;23:109CrossRef Kim H-C. Radioembolization for the treatment of hepatocellular carcinoma. Clin Mol Hepatol 2017;23:109CrossRef
8.
Zurück zum Zitat Liver EAFTSOT. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236. Liver EAFTSOT. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
9.
Zurück zum Zitat Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011;53:1020CrossRef Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md.) 2011;53:1020CrossRef
10.
Zurück zum Zitat Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–380CrossRef Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358–380CrossRef
11.
Zurück zum Zitat Gaba RC, Lewandowski RJ, Hickey R et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Intervent Radiol JVIR 2016;27:457CrossRef Gaba RC, Lewandowski RJ, Hickey R et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Intervent Radiol JVIR 2016;27:457CrossRef
12.
Zurück zum Zitat Padia SA, Lewandowski RJ, Johnson GE et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol JVIR 2017;28:1CrossRef Padia SA, Lewandowski RJ, Johnson GE et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol JVIR 2017;28:1CrossRef
13.
Zurück zum Zitat Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1031–1036CrossRef Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin–bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1031–1036CrossRef
14.
Zurück zum Zitat Kadalayil L, Benini R, Pallan L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565–2570CrossRef Kadalayil L, Benini R, Pallan L et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565–2570CrossRef
15.
Zurück zum Zitat Nam JY, Choe AR, Sinn DH et al. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:1–14CrossRef Nam JY, Choe AR, Sinn DH et al. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function. BMC Cancer 2020;20:1–14CrossRef
16.
Zurück zum Zitat Yasui Y, Tsuchiya K, Kurosaki M et al. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442–450CrossRef Yasui Y, Tsuchiya K, Kurosaki M et al. Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 2018;48:442–450CrossRef
17.
Zurück zum Zitat Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AXJLC. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer 2017;6:360–374CrossRef Costentin CE, Ferrone CR, Arellano RS, Ganguli S, Hong TS, Zhu AXJLC. Hepatocellular carcinoma with macrovascular invasion: defining the optimal treatment strategy. Liver Cancer 2017;6:360–374CrossRef
18.
Zurück zum Zitat El Fouly A, Ertle J, El Dorry A et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627–635CrossRef El Fouly A, Ertle J, El Dorry A et al. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627–635CrossRef
19.
Zurück zum Zitat Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol 2013;36:714–723CrossRef Moreno-Luna LE, Yang JD, Sanchez W et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Interv Radiol 2013;36:714–723CrossRef
20.
Zurück zum Zitat Lobo L, Yakoub D, Picado O et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Interv Radiol 2016;39:1580–1588CrossRef Lobo L, Yakoub D, Picado O et al. Unresectable hepatocellular carcinoma: radioembolization versus chemoembolization: a systematic review and meta-analysis. Cardiovasc Interv Radiol 2016;39:1580–1588CrossRef
21.
Zurück zum Zitat Strigari L, Sciuto R, Rea S et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377–1385CrossRef Strigari L, Sciuto R, Rea S et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med 2010;51:1377–1385CrossRef
22.
Zurück zum Zitat Weng Z, Ertle J, Zheng S et al. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS One 2013;8:e82225CrossRef Weng Z, Ertle J, Zheng S et al. A new model to estimate prognosis in patients with hepatocellular carcinoma after Yttrium-90 radioembolization. PLoS One 2013;8:e82225CrossRef
23.
Zurück zum Zitat Lee JS, Lee HA, Jeon MY et al. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. Eur J Gastroenterol Hepatol 2020;32:739–747CrossRef Lee JS, Lee HA, Jeon MY et al. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. Eur J Gastroenterol Hepatol 2020;32:739–747CrossRef
Metadaten
Titel
A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC
verfasst von
Joon Yeul Nam
Yun Bin Lee
Jeong-Hoon Lee
Su Jong Yu
Hyo-Cheol Kim
Jin Wook Chung
Jung-Hwan Yoon
Yoon Jun Kim
Publikationsdatum
04.02.2021
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 1/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06843-4

Weitere Artikel der Ausgabe 1/2022

Digestive Diseases and Sciences 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.